
Docandu is a digital health platform offering a suite of applications and services that enable users to manage their health and receive reliable medical advice instantly. The platform features a digital medical record system, AI-powered symptom checker, telemedicine consultations, and secure sharing of medical data with doctors worldwide. It serves both individual users and businesses, providing innovative, economical, and accessible healthcare solutions. Docandu supports over 42,000 patients and collaborates with respected healthcare companies and public institutions, positioning itself as a trusted and award-winning leader in digital health in Greece and beyond.

Docandu is a digital health platform offering a suite of applications and services that enable users to manage their health and receive reliable medical advice instantly. The platform features a digital medical record system, AI-powered symptom checker, telemedicine consultations, and secure sharing of medical data with doctors worldwide. It serves both individual users and businesses, providing innovative, economical, and accessible healthcare solutions. Docandu supports over 42,000 patients and collaborates with respected healthcare companies and public institutions, positioning itself as a trusted and award-winning leader in digital health in Greece and beyond.
Product: Digital health platform: mobile app, AI symptom checker, teleconsultations, electronic health record vault
Geography / Market: Founded and developed in Greece; operates in the UK and Europe; linked to London and Greece
Scale: Claims supporting between 42,000 and 100,000+ patients (sources report both figures)
Team size: Approximately 8 employees (reported)
Funding (publicly reported): Total funding reported as $180,000 (last public round date 2019-12-01); last round type listed as equity crowdfunding
Consumer digital health, telemedicine, electronic health records, symptom triage
2017
Digital health / Healthtech
180000.00
Last publicly recorded round type listed as equity crowdfunding.